🇺🇸United States·April 01, 2026·daily

Nasdaq 100 Stocks SEC Filings — April 01, 2026

Across 18 NASDAQ-100 related SEC filings from April 1, 2026, dominant themes include transformative M&A activity (CWBC merger, KDP JDE Peet's acquisition, LUNR $800M Lanteris buy, CYH $459M asset sale) signaling consolidation in banking, beverages, space, and healthcare, with combined entities boasting $5B+ assets or $16B+ revenues. Period-over-period trends show revenue growth in land development (MLP +68% YoY to $19.5M, leasing +1000% YoY to $5.8M) and financing inflows (FF +100% YoY cash to $161.4M), but persistent operating losses (FF $331M FY2025, MLP net loss +43% to $10.6M) and pro forma declines (CYH revenues - $327M). Positive catalysts include Nasdaq compliance regains (Immunic), product validations (AITX), and equity turnarounds (FF stockholders' equity +$7.7M from negative), while neutral proxy filings (UCBI, Intellicheck) and institutional ownership (WMG 13G 5.1%) indicate routine governance. Portfolio-level patterns reveal mixed sentiment (7 positive/mixed growth, 9 neutral), with capital raises via stock sales (Cottonwood $3.6M) and debt optimization supporting turnarounds amid Nasdaq bid price pressures (FF notice). Market implications favor M&A beneficiaries for near-term synergies but flag liquidity risks in loss-making firms.

8 high priority10 medium18 total filings

🇺🇸United States·April 01, 2026·daily

S&P 500 Financials Sector SEC Filings — April 01, 2026

Across 50 SEC filings from the USA S&P 500 Financials stream (broadly including banks, funds, REITs, and related sectors), overarching themes reveal robust M&A/divestiture activity (10+ deals like CWBC merger, CHS $459M sale, Duke $2.48B divestiture), mixed financial performance with bifurcation—revenue grew +17-52% YoY in 9 firms (avg +28%) but plunged -25-78% in 8 (avg -52%), and margin expansions (+900bps in AIDX, +140bps ASE) offsetting compressions. Capital allocation favors returns ($766M WY cash to SH, Cal-Maine $24.3M buyback/$0.36 div), but small caps/biotechs show dilution risks via warrants/placements (e.g., LABT $7.5M pref, Cadrenal inducement). Forward-looking catalysts include growth targets (WY $1.5B EBITDA by 2030, Lamb Weston raised FY26 guidance $6.45-6.55B sales), fund conversions (TCW Jun 2026), and AGMs (WY May 15). Sparse insider data shows no major sales/buys, but mgmt conviction via promotions/div hikes. Portfolio-level: Financials/funds stable (Nuveen $120M Q1 subs), while cyclicals/commodities volatile; actionable now—favor M&A beneficiaries amid reg risks (LFTD hemp bans).

32 high priority18 medium50 total filings

🇺🇸United States·April 01, 2026·daily

S&P 500 Consumer Staples Sector SEC Filings — April 01, 2026

Across 50 SEC filings from the S&P 500 Consumer Staples stream (April 1, 2026), dominant themes include proxy season acceleration with 20+ DEF 14A/DEFA14A filings for May 2026 annual meetings emphasizing director elections, say-on-pay, and auditor ratifications, alongside mixed Q3/FY2025 results showing organic sales resilience (e.g., Conagra +2.4% organic vs -1.9% reported YoY) but widespread margin compression and EBITDA declines in staples like Lamb Weston (-27% adj EBITDA despite +3% sales YoY). M&A activity surges with Keurig Dr Pepper's 96.22% acquisition of JDE Peet’s (EUR 9.9B 2025 sales) for a YE2026 coffee spin-off and Cyclerion's dilutive merger (1.5% ownership retention). Period-over-period trends reveal revenue volatility (Safe & Green +3,900% YoY to $8.2M but loss widened to $16M; Rocky Mountains -50.5% Q1 YoY), improving losses in biotech (Monopar -12% YoY), and capital returns via dividends (Armour $0.24/share, Lamb $0.38) and buybacks (IPG $50M, DFIN $172M record). Forward-looking signals mixed: Lamb Weston raised FY2026 sales/EBITDA midpoints, Conagra narrowed to margin high-end ~11.0-11.5%, with catalysts like BioXcel FDA PDUFA Nov 14, 2026. Leadership churn prominent (6+ CFO/GC changes), no widespread insider selling/buying patterns noted. Portfolio implications: Favor M&A/transforming staples (KDP) over margin-squeezed peers; monitor May proxies for governance shifts amid sector resilience via organic growth offsetting inflation.

24 high priority26 medium50 total filings

🇺🇸United States·April 01, 2026·daily

S&P 500 Industrials Sector SEC Filings — April 01, 2026

Across 50 SEC filings from S&P 500 Industrials and related entities on April 1, 2026, sentiment is predominantly mixed (14/50), with positive tones in M&A completions, dividend declarations, and strong FY2025 results (e.g., L3Harris $21.9B revenue + backlog growth), offset by revenue declines (avg -10% YoY in 7 firms like Innate Pharma -78%, Bassett -2.2%) and widening losses (e.g., Safe & Green net loss +79% to $16M). Period-over-period trends show revenue growth in 6/20 quantifiable filers (e.g., URBN +11.1%, Enphase $1.5B), margin expansions in outperformers (L3Harris + to 15.8%, URBN + to 36%), but compression elsewhere (Bassett -80bps); capital allocation favors dividends (5 declarations, e.g., Global Net Lease $0.19/share) and buybacks (URBN $177M, IPG $50M). M&A activity peaks with Community West-USFO merger ($185M), property dispositions boosting liquidity (Medalist cash to $19M), and capital raises (Charlotte's Web $75M BAT commitment). Insider activity sparse, but management conviction seen in approvals (Golden Entertainment 98% MTA vote). Forward catalysts cluster in May-Jun 2026 proxy/AGM season (L3Harris May 11, Enphase May 13), signaling portfolio rotation opportunities amid volatile direct listings (Lakewood-Amedex) and delisting risks (Safe & Green, Faraday). Overall, industrials exhibit resilient capital returns but bifurcated growth, favoring selective longs in defense/energy storage over cyclicals.

25 high priority25 medium50 total filings

🇺🇸United States·April 01, 2026·daily

S&P 500 Energy Sector SEC Filings — April 01, 2026

The USA S&P 500 Energy stream reflects a very quiet session dominated by routine proxy filings from ONEOK and SunCoke Energy, with neutral sentiment across three filings (materiality 4-6/10) focusing on standard governance matters like director elections, auditor ratifications, and say-on-pay votes ahead of May 2026 virtual AGMs. Hall Chadwick Acquisition Corp's 8-K stands out as the most significant development (positive sentiment, 8/10 materiality), announcing a non-binding LOI with REEcycle Holdings for a potential de-SPAC transaction, signaling early M&A activity in energy-adjacent recycling. No explicit period-over-period financial trends (YoY/QoQ revenue, margins) or insider trading activity disclosed across filings, indicating stable but unremarkable operational momentum; board metrics at SunCoke show consistent 2025 activity with 10 board meetings and 15 committee meetings at >75% attendance versus typical sector norms of 8-12 meetings. Forward-looking elements highlight auditor engagements through Dec 31, 2026, and AGM catalysts on May 14-20, 2026. Portfolio-level themes include strong board independence (SunCoke: 5/6 independent directors) and governance continuity, implying low near-term volatility but limited alpha catalysts beyond Hall Chadwick's deal potential. Overall implications: defensive positioning for Energy sector amid proxy season, with watch for shareholder vote outcomes.

3 high priority1 medium4 total filings

🇺🇸United States·April 01, 2026·daily

Dow Jones 30 Stocks SEC Filings — April 01, 2026

Across 50 SEC filings from Dow Jones 30-related entities and peers on April 1, 2026, overarching themes include robust M&A activity (e.g., Community West merger completion, SharonAI $1.25BN deal, Ondas acquisition), mixed 10-K results with strong revenue growth (avg +100% YoY in growth outliers like Amaze Holdings +558%, Charlie's +169%) but persistent net losses and impairments, and proxy season ramp-up with 15+ AGMs in May 2026. Period-over-period trends show revenue expansion in 12/20 10-Ks (e.g., URBAN +11.1% to $6.2B, ASIAFIN +51.6%), but margin compression or widened losses in 14 cases (e.g., NIKE gross profit -3.1% YoY Q3), alongside positive capital returns like Lamb Weston $0.38 dividend and Las Vegas Sands $2.94B buybacks/dividends. Critical developments feature SPAC mergers progressing (Brag House extension to May 29), Nasdaq delisting risks (Brand House), and forward guidance raises (Lamb Weston FY2026 sales $6.45-6.55B). Portfolio-level patterns indicate sector rotation toward AI/tech (SharonAI, BSTR Bitcoin treasury) amid blue-chip stability, with 8 positive sentiments on deals vs 18 mixed on financials, signaling selective opportunities in consolidations despite operational pressures.

30 high priority20 medium50 total filings

🇺🇸United States·April 01, 2026·daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 01, 2026

The 50 filings reveal polarized performance in the Consumer Discretionary stream, with standout revenue growth in apparel/retail like URBN (+11.1% YoY sales to $6.2B, op income +27.8%) and niche players (ASIAFIN +51.6% YoY, Safe & Green x40 to $8.2M) contrasting sharp declines in food/retail (Cal-Maine Q3 sales -53% YoY, net income -90.1%; Bassett -2.2% sales, op income -52.9%) and EVs (SHF -50% revenue). Margin trends mixed: expansions in URBN (gross to 36.0%) but compressions averaging -100bps across 5 reporters (Bassett -80bps, Nike gross -3.1% Q3 YoY). Capital allocation emphasizes returns with buybacks (URBN $177M/3.7M shares, Cal-Maine $24.3M) and dividends (multiple payable Apr-May 2026). Forward catalysts cluster Q2: earnings (O'Reilly, Blue Owl May), AGMs (URBN June 3, Cinemark May 14), M&A closes (Cal-Maine Creighton). Regulatory risks (LFTD hemp bans threatening 52% sales by Nov 2026) and listing issues (Faraday Nasdaq bid <1) heighten volatility. Portfolio implication: favor resilient retail growth plays amid cyclical pressures.

22 high priority28 medium50 total filings

🇺🇸United States·April 01, 2026·daily

S&P 500 Healthcare Sector SEC Filings — April 01, 2026

Across 50 SEC filings from the USA S&P 500 Healthcare stream (with broader US equity context), dominant themes include a wave of proxy statements (DEF 14A/DEFA14A) for May 2026 annual meetings signaling governance focus amid neutral sentiment; aggressive M&A in regional banks adding $1B+ in assets (e.g., Fulton, CVB, Associated Banc); and mixed biotech performance with 7/12 healthcare firms reporting widened YoY net losses (avg +70%) from R&D ramps (e.g., Forte +95% expenses) offset by cash infusions and pipeline catalysts. Period-over-period trends show healthcare revenue volatility (Interpace Q4 -26% YoY GAAP but thyroid +14%; iSpecimen tissue rev -54% mix share) contrasted by strong bank deposit/loan growth post-mergers; capital allocation leans toward accretive deals over buybacks (News Corp $1B program outlier). Insider activity limited to routine tax-related sales (CCEP PDMRs net zero accumulation). Critical developments: Biotech catalysts like TuHURA Phase 3 enrollment mid-2027 and Forte 2026 readouts; bank expansions positioning for organic growth; implications favor monitoring healthcare turnarounds amid high burn rates while bank M&A offers stability in uncertain markets.

26 high priority24 medium50 total filings

🇺🇸United States·March 31, 2026·daily

S&P 500 Technology Sector SEC Filings — March 31, 2026

Across 29 diverse SEC filings (primarily small/mid-cap non-tech firms despite S&P 500 Tech stream focus, with Snowflake and SEALSQ as key tech outliers), overarching themes include volatile revenue growth (12/29 firms reported YoY revenue increases averaging +200% in winners like Adia Nutrition +10,885%, but 8/29 declines averaging -25% like Planet Green -35%), persistent net losses widening in 14/29 (avg +50% YoY), offset by positive capital allocation in 5/29 (buybacks, dividends). Margin trends mixed: compression in 7/29 (e.g., BlockchAIn 19% vs prior 37%), improvements in cinema/real estate niches. Critical developments: M&A/mergers (Richmond Mutual, Reading acquisitions), biotech catalysts (Immunic/Imunon Phase 3 data E2026), financing wins (ImmunityBio $75M non-dilutive), but red flags in dilution/negative equity (11/29). Portfolio implications: Favor capital return plays and turnaround bios over loss-making microcaps; tech signals limited but Snowflake guidance reaffirm stable. Sector patterns signal caution on expense surges outpacing sales in growth firms.

18 high priority11 medium29 total filings

🇺🇸United States·March 31, 2026·daily

Nasdaq 100 Stocks SEC Filings — March 31, 2026

Across 35 NASDAQ-100 related SEC filings from March 31, 2026, mixed sentiment dominates (14/35 filings), reflecting narrowed losses in 8 companies (e.g., Reading International -60% YoY net loss improvement, Aqua Metals -8%) amid revenue declines in 7 (avg -5% YoY, led by Intelligent Group -9%). Strong outliers include Commercial Metals +21.6% YoY Q2 sales to $2.13B and Adia Nutrition +10,885% YoY revenue to $700k, while biotech firms like Imunon and ImmunityBio show cost cuts (-23%) and non-dilutive funding ($75M). Capital allocation trends favor returns with 3 buyback/dividend announcements (First Northern 6% shares, Camden $0.42/share), debt reductions (Reading -$32M), and M&A (Richmond Mutual $85M deal). SPACs face heavy redemptions and going concern doubts (Welsbach, Jaws Mustang, Metal Sky), signaling portfolio risks in speculative vehicles. Forward catalysts cluster in May 2026 shareholder votes and biotech data (Immunic Phase 3 end-2026), implying alpha in bancorps/turnarounds but caution on metals/mining impairments. Overall, portfolio-level trends show improving profitability (6/12 annual reports with narrower losses) but rising debt (Commercial Metals doubled LT debt post-acquisition) and dilution (Aditxt shares +113%).

21 high priority14 medium35 total filings

🇺🇸United States·March 31, 2026·daily

S&P 500 Financials Sector SEC Filings — March 31, 2026

Across 50 filings from diverse sectors mislabeled under 'USA S&P 500 Financials' (primarily biotechs, SPACs, tech, and limited true financials like insurers/REITs), mixed sentiment dominates (24/50 mixed), with 12 reporting revenue declines averaging -25% YoY (e.g., Beyond Meat -15.6%, Investview -31%, Co-Diagnostics -84%), offset by cost reductions in 15 firms (avg op ex down 30-50%, e.g., BioAtla R&D -31% YoY). Margin compression prevalent in 8/15 with metrics (avg gross margin -500bps, e.g., Beyond Meat -1000bps FY), but net losses improved in 10 cases via one-offs/gains (e.g., AIRO EBITDA positive turn). M&A surges as lifeline: Centessa/Lilly $6.3B (40% premium, Q3 2026 close), Coursera/Udemy merger (April 9 meetings), Sun Country/Allegiant. True financials stable: Lincoln National $2B credit to 2031, Ashford Hospitality $580M refinance/debt elimination, Old Republic proxy routine. Forward catalysts cluster Q2-Q3 2026 (mergers, approvals, AGMs May), signaling alpha in M&A arb/distressed biotechs amid liquidity crunches (18 firms cash <1yr runway). Portfolio implication: overweight M&A targets, avoid persistent loss-makers without catalysts.

35 high priority15 medium50 total filings

🇺🇸United States·March 31, 2026·daily

S&P 500 Consumer Staples Sector SEC Filings — March 31, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (despite diverse inclusions like CMBS trusts and non-staples), dominant themes are routine CMBS 10-K compliance reports (28/50 filings) affirming servicer adherence with widespread master servicer transitions from Wells Fargo to Trimont LLC effective March 1, 2025, signaling operational stability but no financial upside. Operating companies show mixed period trends: revenue flat/declining in 7/10 with financials (e.g., KORE flat YoY, Movano -57% YoY, Hughes -8% YoY), but loss narrowing in KORE (-57% YoY net loss), BrainStorm (-11% YoY), and Movano (-23% YoY); margin compression in South Dakota Soybean (-40 bps) and Proficient Auto (EBITDA margin -590 bps). Capital allocation highlights Marsh & McLennan $2B record buybacks +10% dividends and SmartStop $1.60 annualized dividend target. Forward catalysts include KORE $726M merger (Q2/Q3 2026), BrainStorm Phase 3b enrollment (~200 pts), and Constellation earnings outlook call. Portfolio-level: 80% neutral sentiment in trusts, mixed in ops cos; no insider trades noted, low M&A in staples core but supply chain stress evident.

43 high priority7 medium50 total filings

🇺🇸United States·March 31, 2026·daily

S&P 500 Industrials Sector SEC Filings — March 31, 2026

Across 50 filings in the USA S&P 500 Industrials stream (broadly encompassing industrials-adjacent sectors like defense, energy services, and construction-related CMBS), a dominant theme is routine compliance in 20+ CMBS 10-Ks with widespread master servicer transitions from Wells Fargo to Trimont LLC effective March 1, 2025, signaling operational stability in commercial real estate financing. Period-over-period trends show mixed financials: revenue growth in 8/15 operating companies averaging +20% YoY (e.g., Dawson Geophysical +16%, Range Resources +11%), but persistent net losses or NAV declines in 7 cases (avg -20% equity/NAV drop); Adjusted EBITDA surges in turnarounds like TruBridge (+51% Patient Care) and Dawson (+139%). Positive M&A and capital allocation stand out, with Red Cat's drone acquisitions ($25M+ earnout), Oramed's asset sale with revenue sharing, Range Resources' $231M buybacks/$86M dividends, and First Northern's 6% share repurchase program (~$15.6M). Biotech/industrials crossovers like Tonix (Lyme Ph1 success) and Telomir (TNBC IND) add forward catalysts, while risks include Lipella bankruptcy and going concern doubts in EMAT. Portfolio-level, 65% neutral/positive sentiment, with cap alloc favoring returns over reinvestment; implications favor selective longs in defense/energy services amid stable RE backdrop.

39 high priority11 medium50 total filings

🇺🇸United States·March 31, 2026·daily

S&P 500 Energy Sector SEC Filings — March 31, 2026

Across 12 filings in the USA S&P 500 Energy intelligence stream, a dominant theme is revenue contraction averaging -25% YoY in 7/10 reporting 10-Ks (e.g., Hughes -8%, Nocopi -29%, Zapata -100%), offset by aggressive opex reductions narrowing net losses in 6/9 loss-making firms (e.g., Nocopi -94% loss improvement, Magellan -44%). Halliburton stands out with resilient $2.9B operating cash flow and $1.6B shareholder returns (85% of FCF) despite -3% revenue, signaling sector strength in services amid North America weakness (-6%). Impairments and one-offs drove volatility (Hughes $1.4B charges), while small caps like Lion Copper flipped to $4.4M net income via deconsolidation gains. Capital allocation leans defensive with buybacks/dividends in Halliburton, contrasted by equity raises and debt issuance (Exxon $169M notes). Portfolio-level trends show margin resilience via cost cuts but cash burn persists in explorers (Lion -70% cash drop), raising liquidity risks. Upcoming catalysts include Halliburton AGM (May 20, 2026) and Howard Hughes acquisition close (Q2 2026), with mixed sentiment (7/12 mixed/negative) implying cautious positioning amid energy transition pressures.

8 high priority4 medium12 total filings

🇺🇸United States·March 31, 2026·daily

Dow Jones 30 Stocks SEC Filings — March 31, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (primarily small-cap and micro-cap names with DJ30 exposure themes), overarching patterns reveal mixed financial performance with 12/20 10-Ks showing revenue declines averaging -15% YoY (e.g., Investview -31%, Nuvve -9.3%), offset by loss improvements in 8/20 cases via cost cuts (e.g., Innovative Payment G&A -46%). Capital raises via PIPEs, preferred stock, and SPAC mergers dominate (e.g., Predictive $343.5M PIPE, Trailblazer SPAC close), alongside M&A activity in defense/tech (Red Cat acquisitions) and airlines (Sun Country merger). Forward-looking catalysts include Keenova's 2026 sales guidance $1.94-2B (+YoY growth) and trial readouts Q2-Q4 2026, while risks cluster around going concerns (VivoSim, Welsbach), dilutions, and impairments. Portfolio-level trends show margin pressures in 7/15 ops-focused firms (avg gross margin -100bps), but improving free cash flow in telco/IoT (KORE +$12.4M YoY). Bullish signals from buybacks (First Northern 6% shares) and distributions (AGL $0.60/share); bearish from Nasdaq delist risks (American Rebel). Implications: Selective opportunities in M&A catalysts and turnarounds amid broad volatility.

33 high priority17 medium50 total filings

🇺🇸United States·March 31, 2026·daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 31, 2026

Across 50 filings from the USA S&P 500 Consumer Discretionary intelligence stream (primarily hotels, retail, though broadened to related filings), mixed sentiment dominates (20/50 filings), with 2025 FY results revealing average revenue growth of ~7% YoY in key operators like Ross Stores (+8%), Check Point (+6.3%), TruBridge (+1%), and Proficient Auto (+78.7%), but widespread margin compression averaging -100bps (e.g., Ross -30bps to 11.9%, Check Point op margin -5.1%) due to rising expenses (R&D +15.7% at Check Point, SG&A +200bps at Ross). Liquidity concerns persist in smaller caps (ENDRA cash $762k, FinTrade net loss +332%), offset by capital allocation strength including buybacks (First Northern 6% shares ~$15.6M, Marsh & McLennan $2B), dividends (SmartStop $1.60 annualized, AGL $0.60/share), and refinancings (Ashford $580M debt elimination). Strategic alternatives (ENDRA, Ashford) and mergers (First Foundation/FirstSun closing Apr 1, 2026) signal potential M&A catalysts, while ETF leadership changes at iShares/21Shares indicate crypto/alt asset stabilization. Hospitality/retail outliers like Ashford (+40bps margins, +2.4% EBITDA) and Ross (+5% comp sales) outperform peers amid sector headwinds, positioning for Q2 2026 catalysts like AGMs and revenue thresholds.

40 high priority10 medium50 total filings

🇺🇸United States·March 31, 2026·daily

S&P 500 Healthcare Sector SEC Filings — March 31, 2026

Dominating the 50 filings are over 30 Citigroup Commercial Mortgage Trust 10-Ks revealing a uniform pattern of master servicer transitions from Wells Fargo Bank to Trimont LLC effective March 1, 2025, across dozens of PSAs, with consistent compliance affirmations signaling CMBS sector stability and no material delinquencies or issues. Healthcare-focused filings (ENDRA Life Sciences, Emmaus Life Sciences, Firefly Neuroscience) exhibit volatile trends: Firefly revenue exploded 957% YoY to $1.14M but losses widened to $19.9M with going concern doubts; ENDRA narrowed FY2025 net loss 39% YoY to $7M via 46% op ex cuts yet cash critically low at $762k prompting strategic review; Emmaus revenues fell 25% YoY with net loss up 16%. Broader portfolio shows revenue divergence with standouts like Kennedy Lewis (+71% YoY income), Proficient Auto (+79% revenue), B. Riley (+$299M FY profit swing) offsetting declines (Investview -31%, Specificity assets -0.25%); capital allocation favors buybacks (News Corp $1B ongoing, Cimpress $200M new). Implications: CMBS servicing consolidation reduces risk premiums; small-cap healthcare biotechs offer high-beta turnaround plays amid liquidity squeezes; monitor strategic catalysts for alpha.

42 high priority8 medium50 total filings

🇺🇸United States·March 30, 2026·daily

S&P 500 Technology Sector SEC Filings — March 30, 2026

Across 17 filings from the USA S&P 500 Technology stream, overarching themes include mixed financial recoveries with revenue growth in 5/10 10-K filers (avg +55% YoY in reporters like Inmune Bio +257%, CareView +9%) but persistent net losses narrowing avg 40% YoY, impairments dragging results (ImmuCell $2.7M, Inmune $16.5M), and Nasdaq compliance risks in biotech-adjacent plays. Capital allocation leans shareholder-friendly with repurchases (Cottonwood 1.37M shares, Atmus $61M) and dividends (Sun Communities increases), while M&A pursuits (AParadise-Enhanced Ltd, Atmus-Koch $1.5B) signal growth ambitions amid activist pressures (Weave). Portfolio-level trends show gross margin expansion in 4/7 reporters (avg +25%, ImmuCell +44%) offset by G&A rises and cash burns, with positive operating cash in ImmuCell (+592% YoY) and CareView turnaround. Critical developments: Nasdaq delist threats (Dyadic dual notices), proxy solicitations (Genco, Sun), and May 2026 catalyst cluster (meetings, compliance plans) imply near-term volatility. Market implications favor monitoring turnarounds with improving ops cash but flag liquidity strains in cash-poor entities (SportsQuest $259 cash).

13 high priority4 medium17 total filings

🇺🇸United States·March 30, 2026·daily

Nasdaq 100 Stocks SEC Filings — March 30, 2026

Across 21 NASDAQ-100 related filings from March 30, 2026, overarching themes include mixed financial turnarounds in small-cap biotech and tech firms with revenue softness offset by margin improvements and positive cash flows (e.g., ImmuCell gross profit +44% YoY, CareView operating cash +$805K), contrasted by Nasdaq delisting risks and impairments; period-over-period trends show 6/15 annual reports with revenue growth averaging +9% YoY (CareView +9%, ImmuCell +4%) but 4 with declines averaging -9% (Intellinetics -8%), alongside net loss improvements in 5 cases (ImmuCell -52%). Positive governance events dominate large caps like Starbucks (98% director support) and Atmus (EBITDA +7.3% YoY, $1.5B acquisition), with capital returns via repurchases (Cottonwood 1.37M shares, Atmus $61M) and debt management (Sun $3B paydown). Biotech highlights clinical progress (PepGen Phase 2 data), while shipping faces oversupply risks; portfolio-level patterns signal selective small-cap alpha from operational pivots amid activist interventions (Weave) and liquidity boosts (Mueller $100M facility), but flag microcap distress (Dyadic deficiency). Market implications favor monitoring May catalysts for compliance and M&A, with relative outperformance in SaaS/software segments.

13 high priority8 medium21 total filings

🇺🇸United States·March 30, 2026·daily

S&P 500 Financials Sector SEC Filings — March 30, 2026

Across 50 SEC filings from diverse S&P 500-adjacent names (heavy biotech/energy tilt despite Financials stream), overarching themes include prolific equity capital raises exceeding $2.5B (e.g., OnKure $150M, Capstone $112.5M, Aprea $30M) funding pipelines/growth but risking dilution; M&A surge with $30B+ EV (Sysco/Jet ro $29.1B, Boston Sci/Penumbra, Affinity $142.8M); mixed FY2025 results in 25/50 with revenue (12 up avg +60% YoY like CBAK Q4 +132%, Fathom +25%; 13 down avg -20% like Soluna -22%, Socket -20%) and gross margins compressing avg -350bps in decliners (CBAK 9.4% vs 23.7%). Losses narrowed in 10 biotechs (avg -40% YoY, e.g., Unicycive -30%, OneMedNet -72%) via R&D cuts but widened in 8 (avg +50%). Forward catalysts cluster in May-Jun 2026 (merger votes, AGMs, PDUFA); capital allocation favors reinvestment over returns (Conoco $9B buybacks/divs outlier). Implications: alpha in accretive M&A/biotech catalysts, caution on dilution/margin squeezes; portfolio trend toward defensive M&A plays amid volatile growth.

27 high priority23 medium50 total filings